Adrian Di Bisceglie

Professor of Internal Medicine at Saint Louis University. Co-Director of the Saint Louis University Liver Center. Past President of AASLD. (@AASLDNews)

[Adrian Di Bisceglie @dibiscam]

Why does our ID have to be scanned at every room @AASLDtweets at the liver meeting? Are we being tracked? Delays entry to rooms. What happens to these data? #lossofprivacy #bigbrother #TLM

[Sandy Simons MD @ERGoddessMD]

If you want to know how it’s going in the ER, last night I saw more patients than I’ve ever seen in a single night shift in my entire career. And I’ve been out of residency since 2005, working only night shifts since 2006.

[Naim Alkhouri @AlkhouriNaim]

Thank you @NatRevGastroHep for highlighting our paper on #NASH drugs. @NoureddinMD @RajVlanchi @dibiscam @JonathanStineMD @Pinnacle_TX @LiverArizona @MadrigalPharma @novonordiskus @InterceptPharma @InventivaPharma

[Adrian Di Bisceglie @dibiscam]

@HepDART 2021 just learned about all the other delta viruses that infect other species. Could they infect humans given the right protein envelope, other than HBsAg? I know I don’t want to be the one studying delta in boa constrictors #HBV #HDV

[Li Ka Shing Institute of Virology @LKSIoV]

Congratulations to our Director, Dr. Lorne Tyrrell, on receiving @HepBFoundation's 2022 Blumberg Prize for his pioneering work on hepatitis B!

[HighTide Therapeutics @HighTideThera]

Great news! Our oral presentation about HTD1801 results in patients w/ #NASH & #diabetes has been selected as one of the ‘Best of The Liver Meeting’ 2021 by @AASLDtweets! Exciting to see the data showcased during closing remarks today. #TLMdX #livertwitter
https://t.co/vIix3s4lfP

[Elizabeth Verna @elizabeth_verna]

Very honored to be in this lineup of brilliant women, summarizing the inspiring work of our community! What a meeting! @CarlaBradyMD @Duke_liverdoc @AASLDtweets @AASLDPresident

[Joanne Hatchett @sjhatch_joanne]

Thank you @ruthanne_pai for highlighting the excellent session Emerging Therapies for #PSC & #PBC. Thanks to @DrCynthiaLevy & @AutoImmuneLiver. #LiverMtg21 @AASLDtweets @EASLnews @PSCPartners @PSCPartnersCa @PSCSupportUK @pscsupportau @EuropeLiver @ERN_RARE_LIVER @blackingastro

[HighTide Therapeutics @HighTideThera]

More HTD1801 #NASH results: 18 weeks of treatment w/ Berberine Ursodeoxycholate in subjects w/ NASH & Type 2 #Diabetes was associated w/ improvements in some non-invasive fibrosis markers. Check out our #TLMdX poster (1191) for more. #livertwitter https://t.co/mY55q1q4vD

[HighTide Therapeutics @HighTideThera]

More HTD1801 #PSC results: 18 weeks of treatment by those previously exposed to UDCA improved biochemical markers of cholestasis & liver injury. Check out our #TLMdX poster presentation (1267) for details. @AASLDtweets #livertwitter https://t.co/SeQ34Za3zG

[HighTide Therapeutics @HighTideThera]

Liver fat content w/ HTD1801 (Berberine Ursodeoxycholate) closely associated with improved glycemic control, weight loss & reduced ALT in patients w/ #NASH? #TLMdX @AASLDtweets #livertwitter https://t.co/pakVJ7OFTp

[HighTide Therapeutics @HighTideThera]

How did our main candidate HTD1801 (Berberine Ursodeoxycholate) perform in patients w/ Primary Sclerosing Cholangitis (#PSC) not previously exposed to UDCA? #TLMdX @AASLDtweets #livertwitter

https://t.co/2Sh6rNkVfM

[Stephen Congly @sconglymd]

Summary slide of NAFLD screening pathways by @QAnstee ; clear that 2 step screening strategy important. #TLMDx #LiverMtg21 #LiverTwitter

[HighTide Therapeutics @HighTideThera]

Ask anyone with a chronic illness: It takes long-term patience to be a long-term patient. Read more about the #PSC experience on the @PSCPartners blog. #PSCAware #livertwitter https://t.co/kEMpGyWAGO

[HighTide Therapeutics @HighTideThera]

How are we hoping to help #PSC patients manage their chronic liver condition? By developing a well-tolerated drug for the difficult-to-treat #raredisease, which currently has no approved therapy. Check out the latest clinical trial results: https://t.co/zjWDLcaXMu #PSCAware

[HighTide Therapeutics @HighTideThera]

New Phase II data is coming! We're excited to be presenting the latest clinical findings in our evaluations of HTD1801 in patients w/ primary sclerosing cholangitis (#PSC) & #NASH at this month's #TLMdX Liver Meeting. Stay tuned for details. #livertwitter
https://t.co/JFNNO3Bxec

[Ravi Nayak, MD,FCCP, FRCP @RaviNayakMD]

Thanks ⁦@dibiscam⁩ , Drs. Bruce Luxon & Jason Taylor for organizing a memorable retirement party for Dr. Bruce Bacon. It was a great opportunity to celebrate a brilliant career and legacy of Dr. Bacon ⁦@slusom⁩ ⁦@SLUHospital⁩ ⁦@slucare⁩ ⁦@SLUgastro⁩

[HighTide Therapeutics @HighTideThera]

Excited to see our recent publication highlighted as a Featured Article on @NatureComms!

Read more about Phase II results of HTD1801 in patients with #NASH and #diabetes in this paper by @dibiscam et al: https://t.co/hhxdJUE4Fl

[Gretchen Winter, MD 🌼 (Warning: Feral) @gretchemaben]

Y’all, our #COVID ICU unit is full. All of our ICUs are full. All of our ICU teams are flooded. Our ED is packed. We are turning away hospital transfers because there isn’t room. The #DeltaVariant is real. Masks work. Vaccines are safe and effective. Please get your vaccine!

[Adrian Di Bisceglie @dibiscam]

Pleased to be attending #2021NASHTAG in person in beautiful Park City UT. My first live conference in more than a year! So great to see friends and colleagues again